TTI.V Thiogenesis Therapeutics Corp.
- Market cap
- CAD 44.8M
- P/E
- -
- P/B
- 6.56x
- ROE
- -71.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is TTI.V undervalued?
Graham numberThe Graham number of Thiogenesis Therapeutics Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Thiogenesis Therapeutics Corp. fundamental analysis
No fundamental analysis for Thiogenesis Therapeutics Corp. yet.
Thiogenesis Therapeutics Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Thiogenesis Therapeutics Corp.
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered…
Full company profileThiogenesis Therapeutics Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Thiogenesis Therapeutics Corp. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -73.4K | -92.7K | -225K | -1.97M | -5.21M | -3.58M | -7.40M | -4.80M |
| EBITDA | -73.3K | - | -224K | -3.92M | -5.21M | -3.58M | -7.40M | -4.80M |
| Net Income | -73.3K | -92.7K | -224K | -3.92M | -5.06M | -3.15M | -7.43M | -4.80M |
| EPS | 0.00 | 0.00 | -0.01 | -0.10 | -0.11 | -0.07 | -0.14 | -0.07 |
| Balance Sheet | ||||||||
| Total Assets | 292K | 146K | 3.43M | 6.29M | 7.24M | 3.98M | 1.81M | 7.41M |
| Total Liabilities | 12.2K | 63.1K | 3.49M | 307K | 1.71M | 558K | 1.24M | 685K |
| Shareholders' Equity | 280K | 83.4K | -61.1K | 5.98M | 5.53M | 3.43M | 574K | 6.72M |
| Cash & Short-term Investments | 184K | 19.2K | 62.5K | 6.20M | 7.08M | 3.85M | 1.62M | 7.27M |
| Cash Flow | ||||||||
| Operating Cash Flow | -200K | -35.9K | -67.1K | -2.09M | -3.25M | -3.92M | -6.03M | -5.39M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -200K | -35.9K | -67.1K | -2.09M | -3.25M | -3.92M | -6.03M | -5.39M |
| Ratios | ||||||||
| ROE | -26.2% | -111.2% | - | -65.6% | -91.6% | -91.8% | -1,292.9% | -71.4% |
| ROA | -25.1% | -63.3% | -6.5% | -62.4% | -69.9% | -79.0% | -409.2% | -64.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Thiogenesis Therapeutics Corp. dividends
Thiogenesis Therapeutics Corp. has not paid dividends in the last 7 fiscal years.
Who owns Thiogenesis Therapeutics Corp.
- Insiders 14.16%
- Institutions 0.00%
- Public & others 85.84%
- Shares outstanding 70.0M
- Free float 55.4M
Thiogenesis Therapeutics Corp. company profile
- Company name
- Thiogenesis Therapeutics Corp.
- Ticker
- TTI.V
- Exchange
- TSX Venture Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 4 King Street West, Toronto, ON, Canada, M5H 1B6
- Phone
- 888-223-9165
- Website
- thiogenesis.com
About Thiogenesis Therapeutics Corp.
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada.
Thiogenesis Therapeutics Corp. management
3- Dr. Patrice P. Rioux M.D., Ph.D.Co-Founder, CEO & Director · born 1951
- Mr. Brook G. Riggins C.F.A.CFO, Secretary & Director · born 1966
- Ms. Mary Jo BaggerConsultant for Clinical Operations